 |
|
Study finds drug can cut chance of a heart attack by more than a third
March 31, 2003Results from the ASCOT (Anglo Scandinavian Cardiac Outcome Trial) study have shown that patients receiving the cholesterol controlling drug, atorvastatin, are more than a third less likely to have heart attacks, and more than a quarter less likely to suffer from strokes.
The results of the study, announced today at the American College of Cardiology annual scientific session in Chicago, USA, and simultaneously published online in the Lancet, show that in a study of more than 10,305 people with high blood pressure and normal or only moderately raised levels of cholesterol, those receiving atorvastatin were 36 percent less likely to suffer from heart attacks, and 27 percent less likely to suffer from strokes.
Professor Peter Sever, from Imperial College London and St Mary's Hospital, London and ASCOT study co-chairman comments: "The results of this study are great news to those suffering from high blood pressure because the use of this drug significantly reduces the likelihood of either a stroke or heart attack, in addition to the benefits they will get from the drugs which lower their blood pressure."
Cholesterol in the blood is the major cause of atherosclerosis. It contributes to fatty deposits in the walls of the arteries leading to the heart and the brain. Eventually it blocks these key arteries, leading to either a heart attack or a stroke, respectively. In people with high blood pressure the risks of heart attack and stroke are increased, therefore a combined intervention to tackle both cholesterol and blood pressure should be doubly beneficial and likely to benefit a large number of "at risk" patients.
The results reported today come from the part of the ASCOT study, based in Denmark, Finland, Norway, Sweden, the UK and Ireland, that was stopped in October last year. Members of ASCOT's Data Safety Monitoring Board, who work independently of the trial investigators and are the only researchers permitted to look at the results of the five-year old trial while it is ongoing, reported that those receiving the atorvastatin were significantly less likely to suffer heart attacks or strokes. As a result this part of the trial was halted early, so those receiving the placebo in the control group could also benefit from the use of atorvastatin.
Professor Björn Dahlöf from the Sahlgrenska University Hospital, Ã-stra, Sweden and ASCOT study co-chairman, adds: "At present, large numbers of people around the world are affected by high blood pressure, with only normal or slightly raised cholesterol, causing significant levels of ill health and mortality. This study shows that statins are effective, lowering cholesterol levels, and reducing the likelihood of heart attacks and strokes."
Patients were only eligible for the cholesterol lowering part of the trial if they had a blood cholesterol level of 6.5 mmol per litre or less - a significantly lower range of cholesterol levels than is usually treated by doctors. This part of the trial is specifically aimed to discover if a statin would confer additional protection against coronary heart disease in hypertensive patients with normal cholesterol levels. Patients with cholesterol levels more than 6.5 mmol/L were conventionally treated and were not randomised to the lipid lowering part of the study.
Statins are drugs designed to lower cholesterol levels by slowing down the production of cholesterol and by increasing the liver's ability to remove the cholesterol already in the blood.
The other primary objective of ASCOT is to compare a new treatment strategy for hypertension against an old one, and discover which is better at preventing heart attacks.
The new treatment is a calcium channel blocker (amlodipine), to which in the majority of patients the angiotensin converting enzyme inhibitor, perindopril, is added to achieve the goal blood pressure. The older treatment is a beta blocker (atenolol), to which in the majority of patients a diuretic, bendrofluazide, is added to achieve goal blood pressure.
By May 2000, 19,342 patients had been entered on the trial and randomly selected to receive one of the two blood pressure lowering strategies. Out of the trial total 10,305 patients with low cholesterol were also randomised to receive either placebo or atorvastatin.
Imperial College, University of London
Cholesterol in the blood is the major cause of atherosclerosis. It contributes to fatty deposits in the walls of the arteries leading to the heart and the brain. Eventually it blocks these key arteries, leading to either a heart attack or a stroke, respectively. In people with high blood pressure the risks of heart attack and stroke are increased, therefore a combined intervention to tackle both cholesterol and blood pressure should be doubly beneficial and likely to benefit a large number of "at risk" patients.
The results reported today come from the part of the ASCOT study, based in Denmark, Finland, Norway, Sweden, the UK and Ireland, that was stopped in October last year. Members of ASCOT's Data Safety Monitoring Board, who work independently of the trial investigators and are the only researchers permitted to look at the results of the five-year old trial while it is ongoing, reported that those receiving the atorvastatin were significantly less likely to suffer heart attacks or strokes. As a result this part of the trial was halted early, so those receiving the placebo in the control group could also benefit from the use of atorvastatin.
Professor Björn Dahlöf from the Sahlgrenska University Hospital, Ã-stra, Sweden and ASCOT study co-chairman, adds: "At present, large numbers of people around the world are affected by high blood pressure, with only normal or slightly raised cholesterol, causing significant levels of ill health and mortality. This study shows that statins are effective, lowering cholesterol levels, and reducing the likelihood of heart attacks and strokes."
Patients were only eligible for the cholesterol lowering part of the trial if they had a blood cholesterol level of 6.5 mmol per litre or less - a significantly lower range of cholesterol levels than is usually treated by doctors. This part of the trial is specifically aimed to discover if a statin would confer additional protection against coronary heart disease in hypertensive patients with normal cholesterol levels. Patients with cholesterol levels more than 6.5 mmol/L were conventionally treated and were not randomised to the lipid lowering part of the study.
Statins are drugs designed to lower cholesterol levels by slowing down the production of cholesterol and by increasing the liver's ability to remove the cholesterol already in the blood.
The other primary objective of ASCOT is to compare a new treatment strategy for hypertension against an old one, and discover which is better at preventing heart attacks.
The new treatment is a calcium channel blocker (amlodipine), to which in the majority of patients the angiotensin converting enzyme inhibitor, perindopril, is added to achieve the goal blood pressure. The older treatment is a beta blocker (atenolol), to which in the majority of patients a diuretic, bendrofluazide, is added to achieve goal blood pressure.
By May 2000, 19,342 patients had been entered on the trial and randomly selected to receive one of the two blood pressure lowering strategies. Out of the trial total 10,305 patients with low cholesterol were also randomised to receive either placebo or atorvastatin.
Imperial College, University of London
Cholesterol Current Events and Cholesterol News RSSStudy suggests dentists can identify patients at risk for fatal cardiovascular event
A new study indicates dentists can play a potentially life-saving role in health care by identifying patients at risk of fatal heart attacks and referring them to physicians for further evaluation.
UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin
Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin.
Researchers identify the three killer indicators that are even worse than high cholesterol
Researchers at the University of Warwick have identified a particular combination of health problems that can double the risk of heart attack and cause a three-fold increase in the risk of mortality.
Can charcoal fight heart disease in kidney patients?
Charcoal may provide a new approach to managing the high rate of heart disease in patients with advanced kidney disease, according to preliminary research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.
Widely used cholesterol-lowering drug may prevent progression
Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease.
Statins show dramatic drug and cell dependent effects in the brain
Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia.
Web-based nutrition program reduces health care costs for employees with cardiac risk factors
Researchers from Boston University School of Medicine (BUSM) and Boston University School of Public Health (BUSPH) have shown that an employer-sponsored, internet-based diet and exercise program shows promise as a low-cost benefit to lower healthcare costs for those at higher risk for above-average costs and healthcare utilization such as cardiac, hyperlipidemia, hypertension or diabetes patients. These findings appear in the current issue of the Journal of Medical Internet Research.
Cholesterol-lowering medicines may be effective against cancer
Statins lower cholesterol by blocking certain enzymes involved in our metabolism.
Experts unveil new CVD guidelines and position papers
Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.
Adding ezetimibe to atorvastatin improves lipid control
Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone.
More Cholesterol Current Events and Cholesterol News Articles
 |
Cholesterol Down: Ten Simple Steps to Lower Your Cholesterol in Four Weeks--Without Prescription Drugs by Janet Brill (Author) Take Control of Your Cholesterol— Without Drugs If you are one of the nearly 100 million Americans struggling with high cholesterol, then Dr. Janet Brill offers you a revolutionary new plan for taking control of your health—without the risks of statin drugs. With Dr. Brill’s breakthrough Cholesterol Down Plan, you simply add nine “miracle foods” to your regular diet and thirty minutes of walking to your daily routine. That’s all. This straightforward and easy-to-follow program can lower your LDL (“bad”) cholesterol by as much as 47 percent in just four weeks. Cholesterol Down explains Dr. Brill’s ten-point plan as well as the science behind it. You’ll learn how each miracle food affects LDL cholesterol and how the foods work together for maximum effect,... |
 |
Benecol Smart Chews, Caramel, 120-Count Soft Chews by Benecol #review { width: auto; margin: auto; padding: 0px 10px 10px 10px; } .caption { font-family: Verdana, Helvetica neue, Arial, serif; font-size: 10px; font-weight: bold; font-style: italic; } .headline { font-family: Verdana, Helvetica neue, Arial, serif; font-size: 13px; font-weight: bold; color: #008000; } ul.indent { list-style: inside disc; text-indent: -15px; } #section-head { width: auto; margin: 0px 0px 10px 0px; padding-top: 5px; padding-bottom: 5px; padding-left: 5px; background: #c4df9b; color: #008000; font-size: 16px; font-weight: bold; font-family: Verdana, Helvetica neue, Arial, sans-serif; border-bottom: 2px solid #008000; border-top: 2px solid #008000; } #section-break { margin-top: 40px; clear: both; } th.reviewclass {... |
 |
The New 8-Week Cholesterol Cure: The Ultimate Program for Preventing Heart Disease by Robert E. Kowalski (Author) The groundbreaking cholesterol-lowering program . . . now even more effective! Robert Kowalski's personal story is legendary. By the age of forty-one, he had suffered a heart attack and had undergone two coronary bypass surgeries. A traditional dietary approach to lowering his cholesterol failed dismally, and faced with the unpleasant alternative of a lifetime on medication, he created a program that proved astonishingly effective for him -- and legions of others worldwide who used it. Today Kowalski has beaten heart disease, lives an unlimited and vigorous lifestyle, and uses no prescription drugs. Now, with new information about risk factors, exercise, and supplements, The New 8-Week Cholesterol Cure is even more powerful in fighting heart disease. It includes: ... |
 |
Twinlab Cholesterol Success, Tablets, 120 tablets by Twinlab Dietary supplement. Clinically proven. Reduces cholesterol up to 24%. Now 40% smaller tablets - easier to swallow. All natural. Clinical research has proven that plant sterols and stanols like those found in the Cholesterol Success ingredient CardioCare, may reduce LDL cholesterol (often described as the bad cholesterol) up to 24% when 1.7 g per day are consumed as part of a healthy diet (Jones et al., AM. J. Clin. Nutr. 1999, 69: 1144-1150.) We are confident our product name does not overstate our promise. Combining Cholesterol Success with proper diet & exercise will help you to achieve success in your fight to improve your cholesterol health. Products containing at least 0.4 g per serving of plant sterols, eaten twice a day with meals for a daily intake of at least 0.8 g, as part of a... |
 |
Eating for Lower Cholesterol: A Balanced Approach to Heart Health with Recipes Everyone Will Love by Catherine Jones (Author), Elaine Trujillo MS RD CNSD MS RD CNSD (Contributor) Eating for lower cholesterol has never been easier, or tastier. High cholesterol is directly associated with heart disease. New national guidelines for healthy cholesterol levels, recently revised to be more stringent, mean millions of Americans need to bring their levels down. While doctors fill out millions of prescriptions for cholesterol-lowering drugs, diet remains a proven, supremely effective way to reduce cholesterol. Now, professional cookbook author and health-conscious chef, Catherine Jones, and one of the nation’s leading nutritionists, Elaine B. Trujillo, offer a wealth of cutting-edge information along with a collection of delicious recipes to help lower your cholesterol levels. Key features of this authoritative, information-packed book include: • An... |
 |
CardioChek Cholesterol Test Strips, 3-Count Containers (Pack of 2) by CardioChek The CardioChek Cholesterol Test Strip provides a quantitative measurement of total cholesterol in whole blood. Cholesterol is an important substance used by the body. Elevated cholesterol is a risk factor for coronary heart disease. A memo chip is provided with each package of test strips and must be properly inserted into the CardioChek meter before performing a test. After the test strip is inserted into the meter and blood sample is applied to the test strip, test results are displayed in about 1 minute. |
 |
Controlling Cholesterol For Dummies (For Dummies (Health & Fitness)) by Carol Ann Rinzler (Author), Martin W. Graf MD (Contributor) Need to get your cholesterol in check? You’ll find the latest information about cholesterol, including treatments, drug information, and dietary advice, in Controlling Cholesterol For Dummies, 2nd Edition, an easy-to-understand guide to cholesterol control. You’ll learn how to lower your numbers and maintain healthy cholesterol levels. You’ll also find out how to eat and exercise properly, use vitamins and supplements, and quit unhealthy habits. You’ll find out cholesterol’s positive functions and why too much can be a bad thing. You can also assess your cholesterol risk by taking your age, sex, ethnicity, and family history into consideration. Find out what you need to ask your doctor about stress tests, ECBT, and angiograms to check for plaque buildup. Design a... |
 |
What Your Doctor May Not Tell You About(TM) : Cholesterol: The Latest Natural Treatments and Scientific Advances in One Breakthrough Program (What Your Doctor May Not Tell You About...) by Stephen R. Devries (Author), Winifred Conkling (Author) Heart disease is largely preventable, but conventional cholesterol management is often inadequate. According to university cardiologist and leading prevention specialist Dr. Stephen R. Devries, avoiding heart disease requires a far more comprehensive approach that balances new high tech testing with low tech treatments. Now, in WHAT YOUR DOCTOR MAY NOT TELL YOU ABOUT CHOLESTEROL, Dr. Devries combines natural treatments with the latest scientific advances. New types of cholesterol tests are highlighted that go far beyond routine testing to identify hidden risks. Expanding the traditional medical model, Dr. Devries illustrates the role of mind/body interventions, lifestyle, supplements, vitamins, and conservative use of medication for optimal prevention. |
 |
CholesTrak HDL and Total Cholesterol Home Testing Kit by CholesTrak High cholesterol can be a cause of heart attack and stroke. But with early detection of cholesterol trends, heart problems can be treated more effectively. CholesTrak® Total Cholesterol test allows you to determine your cholesterol level quickly, (12 minutes), simply, and conveniently in your own home, office or while traveling. With this easy-to-use kit, you will know in minutes if you have a healthy cholesterol level or should consult your physician. For peace of mind don't take chances, find out today how your cholesterol trend really is. |
 |
The Great Cholesterol Con by Anthony Colpo (Author) heart disease, cholesterol, saturated fat, fat, |
| © 2009 BrightSurf.com |